BIVI - BioVie Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0400
-0.0160 (-28.57%)
At close: 3:18PM EST
Stock chart is not supported by your current browser
Previous Close0.0560
Open0.0560
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0360 - 0.0560
52 Week Range0.0211 - 0.1400
Volume150,247
Avg. Volume145,822
Market Cap32.253M
Beta (3Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA

    SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has submitted for assessment by the U.S. Food and Drug Administration ("FDA") the Phase 2b/3 clinical trial protocol for using BIV201 (continuous infusion terlipressin) to treat ascites due to chronic liver cirrhosis in patients who are refractory to or cannot tolerate diuretic therapy. In April 2019, BioVie reported the top-line results for its Phase 2a clinical trial of BIV201 for the treatment of refractory ascites.

  • Benzinga

    IPO Outlook For The Week: Biotech, Banking and Chinese Fintech

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. BioVie Inc.  (BIVI) will issue more than 1.31 million shares at $11.44 Tuesday ...

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • Benzinga

    The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

    Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...

  • Benzinga

    BioVie IPO: What You Need To Know

    A biotech company that has a mid-stage asset targeting a disease, and currently has no FDA-approved therapies, is eyeing a Nasdaq listing this week. The IPO Terms Santa Monica, California-based BioVie ...

  • Benzinga

    IPO Outlook For The Week: Beauty Treatments, Banking and Liver Therapy

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. AMTD International Inc. (KHIB) will issue nearly 20.8 million shares ...

  • GlobeNewswire

    BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites

    The primary objectives of this initial open-label study were to assess the safety, tolerability, and steady state pharmacokinetics (PK) of terlipressin administered as a continuous infusion for 28 days to cirrhotic patients with refractory ascites.

  • GlobeNewswire

    BioVie to Present at ThinkEquity Conference in NYC on May 2nd

    BioVie Inc. (BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the ThinkEquity Conference on May 2, 2019 in New York City. Event details: BioVie will present a company overview and clinical trial update on Thursday, May 2, 2019 at the Mandarin Oriental Hotel in New York City at 2:00 pm Eastern Time.

  • GlobeNewswire

    BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites

    BioVie Inc. (BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites due to advanced liver cirrhosis. “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications,” stated BioVie Chief Medical Officer Patrick Yeramian, MD. “What we have learned from this initial study is informing our next clinical trial design.

  • ACCESSWIRE

    BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)

    LOS ANGELES, CA / ACCESSWIRE / November 28, 2018 / BioVie Inc. (BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BIV201 is a new drug candidate currently being tested in a mid-stage (Phase 2a) clinical study in patients with refractory ascites due to advanced liver cirrhosis.